|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
8,320,000 |
Market
Cap: |
5.08(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.34 - $4.49 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Yumanity Therapeutics is a biopharmaceutical company focused on the discovery and development of disease-modifying therapies for neurodegenerative diseases. Co.'s primary program, YTX-7739, is in development for the potential treatment and disease modification of Parkinson's disease. YTX-7739 targets an enzyme known as stearoyl-CoA desaturase (SCD). Inhibition of SCD in multiple cellular systems, including patient-derived neurons, as well as in a mouse model of Parkinson's disease, has been demonstrated to reverse the toxicity of misfolded alpha-synuclein, a protein strongly associated with Parkinson's disease.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
10,250 |
50,250 |
57,251 |
Total Buy Value |
$0 |
$37,160 |
$130,875 |
$174,456 |
Total People Bought |
0 |
3 |
6 |
6 |
Total Buy Transactions |
0 |
6 |
16 |
18 |
Total Shares Sold |
0 |
0 |
0 |
47,617 |
Total Sell Value |
$0 |
$0 |
$0 |
$88,083 |
Total People Sold |
0 |
0 |
0 |
7 |
Total Sell Transactions |
0 |
0 |
0 |
15 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bartoszek Raymond J. |
Director |
|
2023-12-06 |
4 |
B |
$4.50 |
$1,125 |
D/D |
250 |
17,206 |
2.31 |
-89% |
|
Bartoszek Raymond J. |
Director |
|
2023-12-05 |
4 |
B |
$4.50 |
$4,500 |
D/D |
1,000 |
16,956 |
2.31 |
-89% |
|
Bartoszek Raymond J. |
Director |
|
2023-12-04 |
4 |
B |
$4.33 |
$4,325 |
D/D |
1,000 |
15,956 |
2.31 |
-92% |
|
Iadonato Shawn |
Chief Executive Officer |
|
2023-11-29 |
4 |
B |
$3.51 |
$14,403 |
D/D |
4,100 |
675,230 |
2.81 |
-89% |
|
Philips Craig |
President |
|
2023-11-28 |
4 |
B |
$3.27 |
$9,812 |
D/D |
3,000 |
60,811 |
2.74 |
-87% |
|
Iadonato Shawn |
Chief Executive Officer |
|
2023-11-28 |
4 |
B |
$3.33 |
$2,995 |
D/D |
900 |
671,130 |
2.73 |
-87% |
|
Foote Marion R |
Director |
|
2023-10-11 |
4 |
OE |
$0.14 |
$622 |
D/D |
4,443 |
143,204 |
|
- |
|
Philips Craig |
President |
|
2023-09-21 |
4 |
B |
$2.40 |
$6,970 |
D/D |
2,900 |
57,811 |
2.74 |
8% |
|
Kenny Pauline |
General Counsel & Secretary |
|
2023-09-20 |
4 |
B |
$2.58 |
$3,870 |
D/D |
1,500 |
18,448 |
2.66 |
18% |
|
Iadonato Shawn |
Chief Executive Officer |
|
2023-09-20 |
4 |
B |
$2.50 |
$25,042 |
D/D |
10,000 |
670,230 |
2.81 |
18% |
|
Philips Craig |
President |
|
2023-09-20 |
4 |
B |
$2.54 |
$1,525 |
D/D |
600 |
54,911 |
2.66 |
18% |
|
Bartoszek Raymond J. |
Director |
|
2023-09-19 |
4 |
B |
$2.37 |
$4,745 |
D/D |
2,000 |
14,956 |
2.31 |
10% |
|
Bartoszek Raymond J. |
Director |
|
2023-09-18 |
4 |
B |
$2.08 |
$5,200 |
D/D |
2,500 |
12,956 |
2.39 |
19% |
|
Baker Keith |
Chief Financial Officer |
|
2023-09-18 |
4 |
B |
$2.13 |
$10,673 |
D/D |
5,000 |
16,880 |
2.74 |
19% |
|
Bartoszek Raymond J. |
Director |
|
2023-09-15 |
4 |
B |
$2.18 |
$1,090 |
D/D |
500 |
10,456 |
2.31 |
38% |
|
Guillaudeux Thierry |
Chief Scientific Officer |
|
2023-09-14 |
4 |
B |
$2.00 |
$20,000 |
D/D |
10,000 |
21,696 |
2.74 |
30% |
|
Dylla Scott J. |
Director |
|
2023-07-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,000 |
|
60% |
|
Baker Keith |
Chief Financial Officer |
|
2023-06-16 |
4 |
B |
$2.92 |
$14,600 |
D/D |
5,000 |
11,880 |
2.74 |
22% |
|
Bartoszek Raymond J. |
Director |
|
2023-06-14 |
4 |
OE |
$0.14 |
$8,403 |
I/I |
60,018 |
844,478 |
|
- |
|
Kenny Pauline |
General Counsel & Secretary |
|
2023-06-14 |
4 |
D |
$2.82 |
$2,420 |
D/D |
(858) |
16,948 |
|
- |
|
Philips Craig |
President |
|
2023-06-14 |
4 |
D |
$2.82 |
$35,718 |
D/D |
(12,666) |
54,311 |
|
- |
|
Philips Craig |
President |
|
2023-06-14 |
4 |
OE |
$0.14 |
$193 |
I/I |
1,382 |
34,654 |
|
- |
|
Iadonato Shawn |
Chief Executive Officer |
|
2023-06-14 |
4 |
D |
$2.82 |
$20,978 |
D/D |
(7,439) |
660,230 |
|
- |
|
Iadonato Shawn |
Chief Executive Officer |
|
2023-06-14 |
4 |
OE |
$0.14 |
$193 |
D/D |
1,382 |
667,669 |
|
- |
|
Philips Craig |
President |
|
2023-03-20 |
4 |
S |
$3.29 |
$2,866 |
D/D |
(872) |
66,977 |
|
29% |
|
147 Records found
|
|
Page 1 of 6 |
|
|